Physician profile
Abdul Khan
NPI 1215919881
$7,850.49
in general payments reported to CMS, 2019-2025
30 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,052 · 2020: $2,025 · 2021: $775 · 2022: $535 · 2023: $807 · 2024: $958 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.85 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,857.86 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $623.40 | 2019-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $599.20 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $463.74 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $371.64 | 2021-2025 | Freestyle Libre 3, Jeti |
| Bayer Healthcare Pharmaceuticals INC. | $347.36 | 2021-2025 | |
| Amgen INC. | $287.61 | 2019-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $215.24 | 2021-2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $139.55 | 2023-2025 | |
| Vifor Pharma, INC. | $132.60 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $118.40 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $89.44 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.87 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $68.83 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.71 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $52.41 | 2024 | Rayaldee |
| Akebia Therapeutics INC | $39.75 | 2019-2020 | |
| Lilly USA, LLC | $38.43 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $37.83 | 2024 | |
| Ani Pharmaceuticals, INC. | $33.74 | 2022-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $33.27 | 2019-2021 | |
| Novo Nordisk INC | $30.25 | 2025 | Rybelsus, Ozempic |
| Vantive US Healthcare LLC | $24.19 | 2025 | Renal - Pd |
| Alexion Pharmaceuticals, INC. | $18.40 | 2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $18.36 | 2019 | |
| Aurinia Pharma U.S., INC. | $16.78 | 2024 | Lupkynis |
| Nxstage Medical, INC. | $16.58 | 2024 | |
| Boston Scientific Corporation | $16.19 | 2025 | Varithena Administration Pack |
| Mallinckrodt Hospital Products INC. | $12.71 | 2021 | |
| Pfizer INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.